vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and loanDepot, Inc. (LDI). Click either name above to swap in a different company.
loanDepot, Inc. is the larger business by last-quarter revenue ($310.3M vs $284.0M, roughly 1.1× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -7.2%, a 103.6% gap on every dollar of revenue. On growth, loanDepot, Inc. posted the faster year-over-year revenue change (20.5% vs 9.4%). Over the past eight quarters, loanDepot, Inc.'s revenue compounded faster (18.0% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
LoanDepot, sometimes stylized as loanDepot, is an Irvine, California-based nonbank holding company which sells mortgage and non-mortgage lending products.
ACAD vs LDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $310.3M |
| Net Profit | $273.6M | $-22.5M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | -10.3% |
| Net Margin | 96.3% | -7.2% |
| Revenue YoY | 9.4% | 20.5% |
| Net Profit YoY | 90.3% | 32.4% |
| EPS (diluted) | $1.61 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $310.3M | ||
| Q3 25 | $278.6M | $323.3M | ||
| Q2 25 | $264.6M | $282.5M | ||
| Q1 25 | $244.3M | $273.6M | ||
| Q4 24 | $259.6M | $257.5M | ||
| Q3 24 | $250.4M | $314.6M | ||
| Q2 24 | $242.0M | $265.4M | ||
| Q1 24 | $205.8M | $222.8M |
| Q4 25 | $273.6M | $-22.5M | ||
| Q3 25 | $71.8M | $-4.9M | ||
| Q2 25 | $26.7M | $-13.4M | ||
| Q1 25 | $19.0M | $-21.9M | ||
| Q4 24 | $143.7M | $-33.2M | ||
| Q3 24 | $32.8M | $1.4M | ||
| Q2 24 | $33.4M | $-32.2M | ||
| Q1 24 | $16.6M | $-34.3M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | -10.3% | ||
| Q3 25 | 12.8% | -3.2% | ||
| Q2 25 | 12.2% | -11.4% | ||
| Q1 25 | 7.9% | -16.8% | ||
| Q4 24 | 59.1% | -32.7% | ||
| Q3 24 | 12.6% | 1.1% | ||
| Q2 24 | 12.6% | -29.1% | ||
| Q1 24 | 7.4% | -38.2% |
| Q4 25 | 96.3% | -7.2% | ||
| Q3 25 | 25.8% | -1.5% | ||
| Q2 25 | 10.1% | -4.7% | ||
| Q1 25 | 7.8% | -8.0% | ||
| Q4 24 | 55.4% | -12.9% | ||
| Q3 24 | 13.1% | 0.4% | ||
| Q2 24 | 13.8% | -12.1% | ||
| Q1 24 | 8.0% | -15.4% |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | $0.01 | ||
| Q2 24 | $0.20 | $-0.18 | ||
| Q1 24 | $0.10 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $337.2M |
| Total DebtLower is stronger | — | $2.1B |
| Stockholders' EquityBook value | $1.2B | $386.0M |
| Total Assets | $1.6B | $6.9B |
| Debt / EquityLower = less leverage | — | 5.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $337.2M | ||
| Q3 25 | $258.0M | $459.2M | ||
| Q2 25 | $253.6M | $408.6M | ||
| Q1 25 | $217.7M | $371.5M | ||
| Q4 24 | $319.6M | $421.6M | ||
| Q3 24 | $155.1M | $483.0M | ||
| Q2 24 | $177.1M | $533.2M | ||
| Q1 24 | $204.7M | $603.7M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.0B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.3B |
| Q4 25 | $1.2B | $386.0M | ||
| Q3 25 | $917.3M | $433.3M | ||
| Q2 25 | $822.4M | $439.1M | ||
| Q1 25 | $765.2M | $469.3M | ||
| Q4 24 | $732.8M | $506.6M | ||
| Q3 24 | $577.2M | $592.0M | ||
| Q2 24 | $516.7M | $578.9M | ||
| Q1 24 | $464.0M | $637.3M |
| Q4 25 | $1.6B | $6.9B | ||
| Q3 25 | $1.3B | $6.2B | ||
| Q2 25 | $1.2B | $6.2B | ||
| Q1 25 | $1.1B | $6.4B | ||
| Q4 24 | $1.2B | $6.3B | ||
| Q3 24 | $976.9M | $6.4B | ||
| Q2 24 | $914.1M | $5.9B | ||
| Q1 24 | $855.1M | $6.2B |
| Q4 25 | — | 5.44× | ||
| Q3 25 | — | 4.83× | ||
| Q2 25 | — | 4.70× | ||
| Q1 25 | — | 4.30× | ||
| Q4 24 | — | 4.00× | ||
| Q3 24 | — | 3.31× | ||
| Q2 24 | — | 3.41× | ||
| Q1 24 | — | 3.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $-638.7M |
| Free Cash FlowOCF − Capex | — | $-648.0M |
| FCF MarginFCF / Revenue | — | -208.9% |
| Capex IntensityCapex / Revenue | — | 3.0% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-734.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $-638.7M | ||
| Q3 25 | $74.3M | $43.4M | ||
| Q2 25 | $64.0M | $67.6M | ||
| Q1 25 | $20.3M | $-179.9M | ||
| Q4 24 | $40.4M | $47.7M | ||
| Q3 24 | $63.2M | $-349.2M | ||
| Q2 24 | $25.0M | $-278.3M | ||
| Q1 24 | $29.1M | $-278.5M |
| Q4 25 | — | $-648.0M | ||
| Q3 25 | $73.9M | $38.7M | ||
| Q2 25 | — | $61.4M | ||
| Q1 25 | — | $-186.7M | ||
| Q4 24 | — | $40.8M | ||
| Q3 24 | $63.2M | $-356.4M | ||
| Q2 24 | — | $-285.7M | ||
| Q1 24 | — | $-283.3M |
| Q4 25 | — | -208.9% | ||
| Q3 25 | 26.5% | 12.0% | ||
| Q2 25 | — | 21.7% | ||
| Q1 25 | — | -68.2% | ||
| Q4 24 | — | 15.8% | ||
| Q3 24 | 25.2% | -113.3% | ||
| Q2 24 | — | -107.7% | ||
| Q1 24 | — | -127.2% |
| Q4 25 | — | 3.0% | ||
| Q3 25 | 0.1% | 1.5% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | 0.0% | 2.3% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 2.1% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | -255.05× | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
LDI
Segment breakdown not available.
